That rumor is not possible - Every clinical trial conducted for FDA approval is going to have a written SAP before the trial starts to make sure that analysis of the trial data is not biased by knowing what the results are. This is a key part of the trial design process. NWBO's late update of the SAP is very unusual, but at least has some legitimate rationale due to changes in knowledge of how immune therapies work and the unexpected (not planned when the trial started) availability of extremely long follow-up. They are trying to turn something bad into something good.
Market Data 
Markets 
AI
